ABBV · Forward model · All other
What has to happen in All other
Model as of
This page changes All other inside the complete ABBV model. Every other vertical, corporate programme and valuation assumption stays in the selected portfolio case.
Shares this vertical and portfolio case. Slider and horizon edits stay in your browser.
All other
Basis quarter$1.11B
Final quarter$912M
Implied CAGR−4%
Final revenue mix4%
The residual line disclosed as All other in the 10-Q revenue disaggregation. From 2026 it absorbs the eye care portfolio, which AbbVie stopped breaking out and restated prior periods for; eye care was in structural decline, at $580M and -19% year over year in its last disclosed quarter.
Last four quarters
2025 Q3
$1.17B
Estimated
2025 Q4
$1.20B
Estimated
2026 Q1
$1.02B
Estimated
2026 Q2
$1.11B
Estimated
Eye careOther products
Sequential growth
−1.2%/qtr
decaying toward −0.8%
-1.2% a quarter. The first half fell 10% year over year and the eight-quarter sequential rate is -2.4%.
All other
Latest: $912M (2031Q2E)
| Period | Value |
|---|---|
| 2023Q3 | $1.39B |
| 2023Q4 | $1.41B |
| 2024Q1 | $1.28B |
| 2024Q2 | $1.34B |
| 2024Q3 | $1.25B |
| 2024Q4 | $1.40B |
| 2025Q1 | $1.25B |
| 2025Q2 | $1.12B |
| 2025Q3 | $1.17B |
| 2025Q4 | $1.20B |
| 2026Q1 | $1.02B |
| 2026Q2 | $1.11B |
| 2026Q3E | $1.10B |
| 2026Q4E | $1.08B |
| 2027Q1E | $1.07B |
| 2027Q2E | $1.06B |
| 2027Q3E | $1.05B |
| 2027Q4E | $1.04B |
| 2028Q1E | $1.03B |
| 2028Q2E | $1.02B |
| 2028Q3E | $1.01B |
| 2028Q4E | $997M |
| 2029Q1E | $987M |
| 2029Q2E | $978M |
| 2029Q3E | $969M |
| 2029Q4E | $961M |
| 2030Q1E | $952M |
| 2030Q2E | $944M |
| 2030Q3E | $935M |
| 2030Q4E | $927M |
| 2031Q1E | $919M |
| 2031Q2E | $912M |
Assumptions & reasoning
- Every point in this line is derived, not reported as a portfolio total, and is marked estimated for that reason: it is consolidated net revenues less the five disclosed portfolio totals. The method was tested against disclosure - it reproduces the 10-Q All other line exactly at $1,117M for 2025 Q2 and $1,109M for 2026 Q2.
- Aseasonal: the window-to-window spread of 2.7 to 9.4pp is as large as or larger than the apparent factors, so no calendar shape is encoded.
- Because it is a residual, any reclassification by AbbVie moves it with no operating cause at all. The eye care fold-in is exactly that, and no divestiture is disclosed anywhere in the 10-Q or the release.